- A. Health Biotechnology
- Areas of activity
- In vitro diagnostics
- Therapeutic areas
Founded in 2010, Amadix is a leading molecular diagnostics company focused on developing innovative diagnostic tests for early cancer detection in blood to improve patient survival and quality of life.
The company's non-invasive assays tested in blood are oriented to early cancer detection avoiding the complications and side effects of existing invasive procedures and to improve the accuracy and compliance of currently marketed non-invasive tests.
PreveCol®, one of the company's CE-marked products and available in the market, is an innovative test based on an algorithm that combines clinical characteristics with the analysis of plasma biomarker levels for the early detection of colorectal cancer or advanced adenomas (AA).
The company's test pipeline includes, in addition, two blood-based tests for early detection of lung and pancreatic cancer (DiagnoLung and PancreaDix).